RESEARCH OF THE RANGE OF ANTIHYPERTENSIVE MEDICINES AND ANALYSIS OF ITS ECONOMIC AVAILABILITY UNDER THE CONDITIONS OF THE IMPLEMENTATION OF THE GOVERNMENT PROGRAM "AFFORDABLE MEDICINES"

Abstract

The aim of the work. To conduct a study of the antihypertensive drugs' range presented on the pharmaceutical market of Ukraine and the analysis of its socio-economic availability under the conditions of implementation of the government program "Affordable Medicines in Ukraine".

Materials and Methods. The work was performed using official sources of information, data from which were processed, systematized using statistical, logical and graphical methods.

Results and discussion. The analysis of the assortment of antihypertensive drugs as for 2022 showed that 965 trade names of medicinal products were registered in Ukraine, of which 413 products are combined drugs. Among monomedicines, the largest share in the assortment is angiotensin-converting enzyme (ACE) inhibitors - 23.73 %, angiotensin II receptor blockers - 21.79 %, and β-adrenoblockers (β-AB) - 18.32 %. The share of domestically produced medicinal products is 32.8%. As for combined drugs, the largest number of drugs is the following combinations: angiotensin II receptor blockers with diuretics (26.63%), and ACE inhibitors with diuretics (19.85%). The share of domestic manufacturers of combined antihypertensive drugs is only 17.29%.

It was defined that about 31% of antihypertensive drugs from the analyzed assortment are included in the program "Affordable Medicines". There are no combined antihypertensive drugs in the register of drugs subject to reimbursement. Medicinal products of domestic production, which are included in the program of reimbursement of the cost of pharmaceuticals, make up 61.40% of the total number of trade names. Manufacturers present foreign medicines from Hungary, Germany, India, Slovakia, etc. Calculations of DDD surcharge for drugs that are partially reimbursable, accounting for dosage and packaging were carried out.

The largest share of the assortment of all antihypertensive drugs included in the reimbursement program is β-AB (36.84%) and calcium channel blockers (23.39%). Diuretics accounted for only 15.20%. Only one representative from the group of angiotensin II receptor blockers – losartan and ACE inhibitor – enalapril were included in the reimbursement program.

Conclusions. It is necessary to expand the list of medicines from angiotensin II receptor blockers, ACE inhibitors, and combined drugs in the program "Affordable Medicines" to increase the availability of medicines, improve the supply of patients with the necessary medications and implement modern treatment regimens.